Development of the PARP inhibitor olaparib to generate new therapies for cancer patients

被引：0
|
作者：
O'Connor, Mark J. [1 ]
机构：
[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
来源：
MUTAGENESIS | 2012年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
32
引用
收藏
页码：799 / 799
页数：1
相关论文
共 50 条
  • [21] PARP inhibitor development for systemic cancer targeting
    Zaremba, Tomasz
    Jane-Curtin, Nicola
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2007, 7 (05) : 515 - 523
  • [22] The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
    Lallo, Alice
    Frese, Kristopher K.
    Morrow, Christopher J.
    Sloane, Robert
    Gulati, Sakshi
    Schenk, Maximillian W.
    Trapani, Francesca
    Simms, Nicole
    Galvin, Melanie
    Brown, Stewart
    Hodgkinson, Cassandra L.
    Priest, Lynsey
    Hughes, Adina
    Lai, Zhongwu
    Cadogan, Elaine
    Khandelwal, Garima
    Simpson, Kathryn L.
    Miller, Crispin
    Blackhall, Fiona
    O'Connor, Mark J.
    Dive, Caroline
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (20) : 5153 - 5164
  • [23] The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
    Luis Ordonez, Jose
    Teresa Amaral, Ana
    Carcaboso, Angel M.
    Herrero-Martin, David
    del Carmen Garcia-Macias, Maria
    Sevillano, Vicky
    Alonso, Diego
    Pascual-Pasto, Guillem
    San-Segundo, Laura
    Vila-Ubach, Monica
    Rodrigues, Telmo
    Fraile, Susana
    Teodosio, Cristina
    Mayo-Iscar, Agustin
    Aracil, Miguel
    Maria Galmarini, Carlos
    Tirado, Oscar M.
    Mora, Jaume
    de Alava, Enrique
    [J]. ONCOTARGET, 2015, 6 (22) : 18875 - 18890
  • [24] Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
    Nonnekens, Julie
    van Kranenburg, Melissa
    Beerens, Cecile E. M. T.
    Suker, Mustafa
    Doukas, Michael
    van Eijck, Casper H. J.
    de Jong, Marion
    van Gent, Dik C.
    [J]. THERANOSTICS, 2016, 6 (11): : 1821 - 1832
  • [25] Olaparib. PARP-1 and PARP-2 inhibitor, Oncolytic.
    Vasiliou, S.
    Castaner, R.
    Bolos, J.
    [J]. DRUGS OF THE FUTURE, 2009, 34 (02) : 101 - 105
  • [26] The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model
    Hwang, Kihwan
    Lee, Jin-Han
    Kim, Sang Ho
    Go, Kyeong-O
    Ji, So Young
    Han, Jung Ho
    Kim, Chae-Yong
    [J]. IN VIVO, 2021, 35 (04): : 2015 - 2023
  • [27] Nanoformulation of the PARP Inhibitor Olaparib Enables Radiosensitization of a Radiation-Resistant Prostate Cancer Model
    Baldwin, P.
    Van De Ven, A. L.
    Seitzer, N.
    Clohessy, S.
    Cormack, R. A.
    Makrigiorgos, M.
    Pandolfi, P. P.
    Sridhar, S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E595 - E595
  • [28] RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
    Min, Ahrum
    Im, Seock-Ah
    Yoon, Young-Kwang
    Song, Sang-Hyun
    Nam, Hyun-Jin
    Hur, Hyung-Seok
    Kim, Hwang-Phill
    Lee, Kyung-Hun
    Han, Sae-Won
    Oh, Do-Youn
    Kim, Tae-You
    O'Connor, Mark J.
    Kim, Woo-Ho
    Bang, Yung-Jue
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) : 865 - 877
  • [29] PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance
    Dedes, K. J.
    Wilkerson, P.
    Wetterskog, D.
    Lambros, M. B.
    Natrajan, R.
    Tan, D. S.
    Campion-Flora, A.
    Rodrigues, D. N.
    Gauthier, A.
    Daley, F.
    Lord, C. J.
    Kaye, S. B.
    Ashworth, A.
    Reis-Filho, J. S.
    [J]. LABORATORY INVESTIGATION, 2012, 92 : 265A - 265A
  • [30] THE COMBINATION PARP INHIBITOR OLAPARIB WITH TEMOZOLOMIDE IN AN EXPERIMENTAL GLIOBLASTOMA MODEL
    Hwang, Kihwan
    Go, Kyeong-O
    Kim, Sang Ho
    Lee, Hyunwoo
    Han, Jung Ho
    Kim, Chae-Yong
    [J]. NEURO-ONCOLOGY, 2020, 22 : 66 - 66
12345